EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

Gideon M. Hirschfield, Ulrich Beuers, Christophe Corpechot, Pietro Invernizzi, David Jones, Marco Marzioni, Christoph Schramm

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

Original languageEnglish (US)
JournalJournal of Hepatology
DOIs
StateAccepted/In press - 2017
Externally publishedYes

Fingerprint

Cholangitis
Practice Guidelines
Fibric Acids
Ursodeoxycholic Acid
Budesonide
End Stage Liver Disease
Biliary Liver Cirrhosis
Hepatitis
Liver Diseases
Patient Care
Therapeutics
Antibodies
Liver
Serum

Keywords

  • Care pathway
  • Cholestasis
  • Guidelines
  • Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (Accepted/In press). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2017.03.022

EASL Clinical Practice Guidelines : The diagnosis and management of patients with primary biliary cholangitis. / Hirschfield, Gideon M.; Beuers, Ulrich; Corpechot, Christophe; Invernizzi, Pietro; Jones, David; Marzioni, Marco; Schramm, Christoph.

In: Journal of Hepatology, 2017.

Research output: Contribution to journalArticle

Hirschfield, Gideon M. ; Beuers, Ulrich ; Corpechot, Christophe ; Invernizzi, Pietro ; Jones, David ; Marzioni, Marco ; Schramm, Christoph. / EASL Clinical Practice Guidelines : The diagnosis and management of patients with primary biliary cholangitis. In: Journal of Hepatology. 2017.
@article{c5930aa7d3644f9a9d021a76cacf202e,
title = "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis",
abstract = "Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.",
keywords = "Care pathway, Cholestasis, Guidelines, Liver",
author = "Hirschfield, {Gideon M.} and Ulrich Beuers and Christophe Corpechot and Pietro Invernizzi and David Jones and Marco Marzioni and Christoph Schramm",
year = "2017",
doi = "10.1016/j.jhep.2017.03.022",
language = "English (US)",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - EASL Clinical Practice Guidelines

T2 - The diagnosis and management of patients with primary biliary cholangitis

AU - Hirschfield, Gideon M.

AU - Beuers, Ulrich

AU - Corpechot, Christophe

AU - Invernizzi, Pietro

AU - Jones, David

AU - Marzioni, Marco

AU - Schramm, Christoph

PY - 2017

Y1 - 2017

N2 - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

AB - Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

KW - Care pathway

KW - Cholestasis

KW - Guidelines

KW - Liver

UR - http://www.scopus.com/inward/record.url?scp=85017552637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017552637&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2017.03.022

DO - 10.1016/j.jhep.2017.03.022

M3 - Article

AN - SCOPUS:85017552637

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -